Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia.

[1][2][3] One clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.

[4] In 2010 favourable results were announced from the phase II trial for Hodgkin's lymphoma.

[5] MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.

[6] It works by inhibiting mainly histone deacetylase 1 (HDAC1), but also HDAC2, HDAC3, and HDAC11.